首页 >
法规速递
-
Document: Opinion of the CVMP on the establishment of maximum residue limits: Fluralaner ( EMEA/V/MRL/004380/EXTN/0002)-2026/3/6
2026-03-09查看详情 > -
Document: Highlights - EMA - European Alliance of Associations for Rheumatology (EULAR) bilateral meeting - March 2026-2026/4/7
2026-04-08查看详情 > -
Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations-2026/5/20
2026-05-21查看详情 > -
国家药监局关于药物非临床安全性评价研究机构信息平台上线运行的通告（2022年 第58号）-2022/12/15
2022-12-19查看详情 > -
Regulatory and procedural guideline: Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products-2023/6/27
2023-06-28查看详情 > -
Final Guidance: Digital Health Technologies for Remote Data Acquisition in Clinical Investigations-2023/12/21
2024-01-03查看详情 > -
国家药监局关于修订天麻制剂、复方石韦胶囊（颗粒、咀嚼片）和喘舒片等药品说明书的公告 （2025年第6号） -2025/1/24
2025-01-24查看详情 > -
关于将乙磺酸尼达尼布软胶囊纳入《以患者为中心的罕见疾病药物研发试点工作计划（“关爱计划”）》试点项目的通知-2025/2/28
2025-03-03查看详情 > -
Document: Antimicrobial Sales and Use (ASU) Platform: Release notes-2025/4/3
2025-04-07查看详情 > -
Document: Article 57 product data-2025/5/14
2025-05-15查看详情 >
